Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens

Journal of Virology

Volumn 85, Issue 18, 2011, Pages 9395-9405

  Chen, Weizao ^a   Feng, Yang ^b   Gong, Rui ^a   Zhu, Zhongyu ^a   Wang, Yanping ^a,b   Zhao, Qi ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD; BLOOD CELL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MOLECULAR LIBRARY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN ISOLATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN UNFOLDING; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANTI-HIV AGENTS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MUTANT PROTEINS; MUTATION, MISSENSE; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN STABILITY; RECEPTORS, VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052499557     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05119-11     Document Type: Article

References (42)

1. Allaway, G. P., et al. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11:533-539.
2. Arthos, J., et al. 2002. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J. Biol. Chem. 277:11456-11464.
3. Bosshart, H., and R. F. Jarrett. 1998. Deficient major histocompatibility complex class II antigen presentation in a subset of Hodgkin's disease tumor cells. Blood 92:2252-2259.
4. Bugelski, P. J., P. A. Thiem, A. Truneh, and D. G. Morgan. 1991. Recombinant human soluble CD4 does not inhibit immune function in cynomolgus monkeys. Toxicol. Pathol. 19:580-588.
5. Chen, W., X. Xiao, Y. Wang, Z. Zhu, and D. S. Dimitrov. 2010. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res. 88:107-115.
6. Chen, W., Z. Zhu, Y. Feng, and D. S. Dimitrov. 2008. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc. Natl. Acad. Sci. U. S. A. 105:17121-17126.
7. Chen, W., Z. Zhu, Y. Feng, and D. S. Dimitrov. 2010. A large human domain antibody library combining heavy and light chain CDR3 diversity. Mol. Immunol. 47:912-921.
8. Chen, W., Z. Zhu, Y. Feng, X. Xiao, and D. S. Dimitrov. 2008. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J. Mol. Biol. 382:779-789.
9. Dalgleish, A. G., et al. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767.
10. Deen, K. C., et al. 1988. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 331:82-84.
11. DeVico, A., et al. 2007. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. U. S. A. 104:17477-17482.
12. Dey, B., C. S. Del Castillo, and E. A. Berger. 2003. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol. 77:2859-2865.
13. Feng, Y., et al. 2006. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol. Cancer Ther. 5:114-120.
14. Fletcher, C. V., et al. 2007. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children. J. Allergy Clin. Immunol. 119:747-750.
15. Garlick, R. L., R. J. Kirschner, F. M. Eckenrode, W. G. Tarpley, and C. S. Tomich. 1990. Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. AIDS Res. Hum. Retroviruses 6:465-479.
16. Germain, R. N. 1997. T-cell signaling: the importance of receptor clustering. Curr. Biol. 7:R640-E644.
17. Gong, R., et al. 2009. Engineered human antibody constant domains with increased stability. J. Biol. Chem. 284:14203-14210.
18. Kahn, J. O., et al. 1990. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the AIDS and AIDS-related complex. A phase 1 study. Ann. Intern. Med. 112:254-261.
19. Kubetzko, S., C. A. Sarkar, and A. Pluckthun. 2005. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68:1439-1454.
20. Kwong, P. D., et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678- 682.
21. Kwong, P. D., et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
22. Langner, K. D., et al. 1993. Antiviral effects of different CD4-immunoglobulin constructs against HIV-1 and SIV: immunological characterization, pharmacokinetic data and in vivo experiments. Arch. Virol. 130:157-170.
23. Liao, H. X., et al. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268-282.
24. Maekawa, A., B. Schmidt, B. Fazekas de St. Groth, Y. H. Sanejouand, and P. J. Hogg. 2006. Evidence for a domain-swapped CD4 dimer as the coreceptor for binding to class II MHC. J. Immunol. 176:6873-6878.
25. Martin, L., et al. 2003. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 21:71-76.
26. Meng, T. C., et al. 1995. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:152-160.
27. Moebius, U., P. Pallai, S. C. Harrison, and E. L. Reinherz. 1993. Delineation of an extended surface contact area on human CD4 involved in class II major histocompatibility complex binding. Proc. Natl. Acad. Sci. U. S. A. 90:8259- 8263.
28. Prabakaran, P., et al. 2008. Structure of an isolated unglycosylated antibody C(H)2 domain. Acta Crystallogr. D Biol. Crystallogr. 64:1062-1067.
29. Roben, P., et al. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68: 4821-4828.
30. Ryu, S. E., et al. 1990. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature 348:419-426.
31. Sakihama, T., A. Smolyar, and E. L. Reinherz. 1995. Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc. Natl. Acad. Sci. U. S. A. 92:6444-6448.
32. Schacker, T., et al. 1995. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9:145-152.
33. Schooley, R. T., et al. 1990. Recombinant soluble CD4 therapy in patients with the AIDS and AIDS-related complex. A phase I-II escalating dosage trial. Ann. Intern. Med. 112:247-253.
34. Sharma, D., et al. 2005. Protein minimization of the gp120 binding region of human CD4. Biochemistry 44:16192-16202.
35. Traunecker, A., W. Luke, and K. Karjalainen. 1988. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 331:84-86.
36. Varadarajan, R., et al. 2005. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J. Virol. 79:1713-1723.
37. Wang, J. H., et al. 2001. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc. Natl. Acad. Sci. U. S. A. 98:10799-10804.
38. West, A. P., Jr., et al. 2010. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J. Virol. 84:261-269.
39. Wu, H., P. D. Kwong, and W. A. Hendrickson. 1997. Dimeric association and segmental variability in the structure of human CD4. Nature 387:527-530.
40. Wu, S. J., et al. 2010. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng. Des. Sel. 23:643-651.
41. Zhang, M. Y., et al. 2004. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. 335:209-219.
42. Zhu, Z., et al. 2008. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197:846-853.